0      0

Integrated Safety

‐ Mar 18, 2023 9:00am

This poster reports on data of the safety of avacopan, C5a receptor inhibitor, from two Phase 2 and one Phase 3 studies in 439 patients with ANCA-associated vasculitis. Rates of exposure-adjusted total adverse event (AEs), serious AEs, withdrawal of study medication due to AEs, and pre-specified AEs of interest were calculated based on the integrated data from all three trials.



You must be logged in and own this session in order to post comments.